IDEXX Laboratories, Inc.

NASDAQ:IDXX

Medical - Diagnostics & Research

Healthcare
$698.47 +2.26%

+$12.33 today

Market cap
$55.03B
Beta
1.54
P/E (TTM)
40.8
EPS (TTM)
$13.67
52W Low $506.91High $769.98

Volume 0.37M

Average 0.58M

IDXX Other Financing Activities

Financing cash flows not reported separately.

IDEXX Laboratories, Inc.NASDAQ: IDXX

Other Financing Activities · Q3 FY2026 · quarter ended Sep 2026

Other financing activities turns negative

Q3 FY2026 other financing activities was -$150K, compared with $75.41M a year earlier. Trailing-twelve-month other financing activities was -$11.06M. Over 3 fiscal years it compounded at -24.8% a year.

Context

  • Other financing activities amounted to 0.2% of revenue in FY2025, down 0.1 pp from a year earlier.
  • Other financing activities grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other financing activities holds near -$150K or moves back toward the trailing-twelve-month quarterly average of -$2.77M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$150K-49.7% QoQ
Last fiscal yearDec 2025
-$7.24M-31.3% YoY
LTMSep 2026
-$11.06M+64.4% YoY
Other Financing Activities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.2%——
1 year-31.3%——
3-year CAGR-24.8%——
5-year CAGR——
10-year CAGR——

Other Financing Activities history

USD · from the cash flow

Latest · FY2025
(7.24M) USD
Year-over-year change
+31.3%

Other Financing Activities vs competitors

How IDXX compares with its peers on the latest reported figures

  • IDXX's LTM Sep 2026 other financing activities of $11.06M is the 4th largest of the 5 companies compared; the peer median is $122M.
  • Its year-over-year change of +64.4% is the 2nd highest of 5, against a peer median of -46.1%.
  • Other financing activities amounts to 0.2% of revenue for IDXX, versus a peer median of 0.3%.
IDXX Competitors Peer median
Other Financing Activities for IDXX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ELANElanco Animal Health IncorporatedLTM Sep 2026$631M -3104.8%—12.3%
MRKMerck & Co., Inc.LTM Jun 2026$227M -25.3%-18.3%0.3%
ZTSZoetis Inc.LTM Jun 2026$17M +88.9%-34.1%0.2%
IDXXIDEXX Laboratories, Inc.LTM Sep 2026$11.06M +64.4%-24.8%0.2%
NEOGNeogen CorporationLTM Aug 2026$1.98M -67.0%-62.7%0.2%
Peer median (excluding IDXX) $122M-46.1%-34.1%0.3%

Competitors are the stored peer set for IDXX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income744.84M679.09M845.04M887.87M1.06B
Depreciation & Amortization104.6M111.9M114.91M129.94M145.18M
Deferred Income Tax(3.38M)(35.07M)(48.31M)(24.19M)131.2M
Stock-Based Compensation37.76M49.77M59.74M60.3M0
Change in Working Capital(137.52M)(273.53M)(72.43M)(133.24M)(227.51M)
Accounts Receivables(33.14M)(41.4M)(53.87M)(28.28M)(68.72M)
Inventory(52.92M)(121.73M)(28.65M)(28M)(789K)
Accounts Payables11.23M3.47M(557K)8.09M(8.57M)
Other Working Capital(62.7M)(113.87M)10.65M(85.04M)(149.43M)
Other Non-Cash Items9.25M10.82M7.56M8.34M69.73M
Operating Cash Flow755.55M542.98M906.51M929M1.18B
Capital Expenditures(119.55M)(148.84M)(133.63M)(130.92M)(124.68M)
Acquisitions (Net)(173.42M)(46.51M)0(77.7M)0
Purchases of Investments0(25M)00(756K)
Sales of Investments071.51M01.56M0
Other Investing Activities0(46.51M)8.38M(10M)2.74M
Investing Cash Flow(292.97M)(195.35M)(125.25M)(207.06M)(136.24M)
Debt Repayment23.5M430.5M(404M)(75M)(30.39M)
Common Stock Issued46.57M35.75M47.03M44.49M93.36M
Common Stock Repurchased(746.78M)(819.71M)(71.92M)(837.03M)(1.22B)
Dividends Paid00000
Other Financing Activities(20.7M)(17.04M)(13.11M)(10.53M)(7.24M)
Financing Cash Flow(697.41M)(370.94M)(442M)(878.07M)(1.16B)
Effect of Forex Changes(4.64M)(8.61M)2.13M(9.53M)11.2M
Net Change in Cash(239.47M)(31.91M)341.39M(165.67M)(108.2M)
Free Cash Flow636M394.15M772.88M798.08M1.05B

IDEXX Laboratories, Inc.

NASDAQ:IDXX

Intrinsic Alpha fair value

Locked

Current Price

$698.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.